5 results
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
22 May 23
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
4:53pm
Medicines is committed to patient access and affordability for its approved medicines through YourBlueprint®, which is designed to provide dedicated
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
16 Jun 21
FDA Approves Blueprint Medicines’ AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
5:14pm
Medicines provides access and affordability programs through YourBlueprint™. For more information, visit YourBlueprint.com or call 1-888-BLUPRNT (1-888-258
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
1 Dec 20
Other Events
4:23pm
. As part of this commitment, Blueprint Medicines is providing YourBlueprint™, a patient support program that offers access and affordability solutions
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
8 Sep 20
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment
6:03am
is providing YourBlueprint™, a patient support program that offers access and affordability solutions for individuals receiving GAVRETO. For more information
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
9 Jan 20
Other Events
4:04pm
their treatment journey. As part of this commitment, Blueprint Medicines is introducing YourBlueprint™, a patient support program that offers access … and affordability solutions for individuals receiving AYVAKIT. For more information, visit YourBlueprint.com or call 1-888-BLUPRNT (1-888-258-7768
- Prev
- 1
- Next